UCB touts an­oth­er pso­ri­a­sis win, this time over Cosen­tyx, as they look to break in­to packed mar­ket

Long a qui­et play­er in the R&D game, UCB made a splash last fall when they an­nounced that their ex­per­i­men­tal pso­ri­a­sis drug bimek­izum­ab had de­feat­ed J&J’s block­buster Ste­lara in a Phase III tri­al. It was the first of three Phase II­Is meant to launch the can­di­date in­to a crowd­ed mar­ket dom­i­nat­ed by some of the in­dus­try’s biggest drug­mak­ers. The sec­ond an­nounce­ment came two months lat­er with a win over Ab­b­Vie’s Hu­mi­ra.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.